Eli Lilly Won't Raise Drug Prices This Year, CEO Says

The video discusses Eli Lilly's strong quarterly performance, highlighting a 9% revenue growth and a 35% increase in earnings. The company is focusing on new product innovations and collaborations, including a non-opioid pain medicine with Pfizer. Eli Lilly plans to spin off its animal health business through an IPO to maximize shareholder value. The impact of the IPO on margins is discussed, along with the company's stance on drug pricing and trade issues, emphasizing the importance of free trade and addressing market access challenges.

What are some of the new products that Eli Lilly is expecting to launch in the near future?

Discuss the importance of the acquisition of Armor Biosciences for Eli Lilly's oncology strategy.

What impact could trade disruptions have on Eli Lilly's operations?